EMA Clarifies Exposure Limits, Risk-Based Models for the Prevention of Contamination in Drug Manufacturing

Drug Industry Daily
The EMA is clarifying agency expectations on the implementation of risk-based models and exposure limits to prevent cross-contamination during manufacturing in a Q&A guideline, telling manufacturers that all products should have health-based exposure limits (HBEL).

To View This Article:


Subscribe To Drug Industry Daily